A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Fluticasone furoate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 22 May 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
- 28 Jun 2012 Planned number of patients changed from 599 to 624 as reported by European Clinical Trials Database.
- 17 Feb 2012 Results published in Respiratory Medicine.